picking the bottom , page-5

Surprisingly low volume considering that these announcements are the only non-positive announcements the company has made.

Unfortunate that Cripto-1 was a dead end, but good ML has cut the program early. (Should also instill confidence that they believe in CVac.)

And Dubai was a 'nice to have', and perhaps a loophole that would allow anecdotal patient results to emerge pre Phase 3 completion. A pity that legislation and red tape got in the way of potentially saving patient lives.

But I doubt both programs were priced into the current SP in any significant way.
I would hope that this streamlining serves to focus both the company and the shareholders.